'Advanced nsclc' presentation slideshows

Elderly Patients with Advanced NSCLC: Emerging Role of Targeted Therapy

Elderly Patients with Advanced NSCLC: Emerging Role of Targeted Therapy. Corey J Langer MD, FACP Professor of Medicine Director of Thoracic Oncology University of Pennsylvania, Philadelphia, PA Corey.langer@uphs.upenn.edu. Demographics of Lung Cancer in the Older Patient.

904 views • 72 slides

Program Goals

Program Goals. Introduction. Using Vaccines in the Treatment of NSCLC. Vaccine Approach in NSCLC Targeting Tumor Antigens. Vaccines Evaluated in Phase 3 Lung Cancer Trials Study Designs. Vaccines Evaluated in Phase 3 Lung Cancer Trials (cont) Study Designs.

715 views • 60 slides

Personalized Treatment of Advanced NSCLC A Coordinated Multidisciplinary Approach

Personalized Treatment of Advanced NSCLC A Coordinated Multidisciplinary Approach. Program Goals. Treatment of Advanced NSCLC. Impact of NSCLC-NOS on Treatment Selection in Advanced NSCLC. Impact of NSCLC-NOS on Treatment Selection in Advanced NSCLC (cont). IPASS: Study Design.

953 views • 58 slides

703 views • 53 slides

Advanced Squamous Cell Carcinoma of the Lung Is the Time Now?

Advanced Squamous Cell Carcinoma of the Lung Is the Time Now?. Program Goals. Introduction. Parsing Lung Cancer to Optimize Patient Management. Recommendations From NCCN NSCLC Guidelines. Recommendations From NCCN NSCLC Guidelines (cont).

643 views • 50 slides

Treatment in Advanced Non-Small Cell Lung Cancer

Treatment in Advanced Non-Small Cell Lung Cancer. NSCLC| Epidemiology- Australia. 5 th most commonly diagnosed cancer in Australia 8.9% of new cancer diagnoses In 2009: 10,193 cases ( 6034 men, 4159 women) Projection to 2020 ? 13,640 Mortality

810 views • 49 slides

1-line Treatment of Advanced-NSCLC WT

296 views • 28 slides

472 views • 26 slides

New Standards of Care in ALK -Translocated Advanced NSCLC

New Standards of Care in ALK -Translocated Advanced NSCLC.

219 views • 21 slides

Redefining Non-small Cell Lung Cancer: The Role of Histology

Redefining Non-small Cell Lung Cancer: The Role of Histology. History of Therapy in Advanced NSCLC: FDA Approval Dates. ECOG 1594: What Did It Teach Us?. Bevacizumab in NSCLC: Key Clinical Outcomes. Grade 3-5 Non-hematologic Toxicity Associated With Bevacizumab. AVAIL Study Design.

412 views • 16 slides

Lung Cancer Basic Overview Patient Forum: 2019

Corey J Langer MD, FACP Director of Thoracic Oncology Abramson Cancer Center Professor of Medicine University of Pennsylvania Philadelphia, PA 19104. Lung Cancer Basic Overview Patient Forum: 2019. What everyone should know about Lung Cancer. World-wide Epidemic

146 views • 14 slides